Uterine Leiomyoma (Uterine Fibroids) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2000

Uterine leiomyoma (uterine fibroids) pipeline market research report provides comprehensive information on the therapeutics under development for Uterine Leiomyoma (Uterine Fibroids), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Uterine Leiomyoma (Uterine Fibroids) and features dormant and discontinued projects.

Key Targets in the Uterine Fibroids Pipeline Market

The key targets in the uterine fibroids pipeline market report are Gonadotropin Releasing Hormone Receptor, Progesterone Receptor, and Collagen. Gonadotropin Releasing Hormone Receptor has the highest number of pipeline products in the uterine fibroids pipeline market.

Uterine Fibroids Pipeline Market, by Targets

Uterine Fibroids Pipeline Market, by Targets

For more target insights, download a free report sample

Key MoA in the Uterine Fibroids Pipeline Market

The key MoA in the uterine fibroids pipeline market report are Gonadotropin Releasing Hormone Receptor Antagonist, Gonadotropin Releasing Hormone Receptor Agonist, Progesterone Receptor Agonist, Collagen Inhibitor, and Progesterone Receptor Antagonist. Gonadotropin Releasing Hormone Receptor Antagonist has the highest number of pipeline products.

Uterine Fibroids Pipeline Market, by MoA

Uterine Fibroids Pipeline Market, by MoA

For more MoA insights, download a free report sample

Key RoA in the Uterine Fibroids Pipeline Market

The key RoA in the uterine fibroids pipeline market report are oral, parenteral, subcutaneous, and intramuscular. Oral has the highest number of pipeline products.

Uterine Fibroids Pipeline Market, by RoA

Uterine Fibroids Pipeline Market, by RoA

For more RoA insights, download a free report sample

Key Molecule Types in the Uterine Fibroids Pipeline Market

The key molecule type in the uterine fibroids pipeline market report are small molecule, synthetic peptide, enzyme, vaccine. Small molecule has the highest number of pipeline products.

Uterine Fibroids Pipeline Market, by Molecule Types

Uterine Fibroids Pipeline Market, by Molecule Types

For more molecule type insights, download a free report sample

Key Companies in the Uterine Fibroids Pipeline Market

The key companies in the uterine fibroids pipeline market report are Kissei Pharmaceutical Co Ltd, Richter Gedeon Nyrt, AbbVie Inc, Bayer AG, Context Therapeutics Inc, Daewoong Pharmaceutical Co Ltd, Endo International Plc, and Eurofarma Laboratorios SA. Kissei Pharmaceutical Co Ltd has the highest number of pipeline products.

Uterine Fibroids Pipeline Market, by Companies

Uterine Fibroids Pipeline Market, by Companies

To know about more companies, download a free report sample

Market report overview

Key targets Gonadotropin Releasing Hormone Receptor, Progesterone Receptor, and Collagen
Key MoA Gonadotropin Releasing Hormone Receptor Antagonist, Gonadotropin Releasing Hormone Receptor Agonist, Progesterone Receptor Agonist, Collagen Inhibitor, and Progesterone Receptor Antagonist
Key RoA Oral, Parenteral, Subcutaneous, and Intramuscular
Key molecule type Small Molecule, Synthetic Peptide, Enzyme, Vaccine
Key companies Kissei Pharmaceutical Co Ltd, Richter Gedeon Nyrt, AbbVie Inc, Bayer AG, Context Therapeutics Inc, Daewoong Pharmaceutical Co Ltd, Endo International Plc, and Eurofarma Laboratorios SA

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Uterine Leiomyoma (Non Malignant Disorders).
  • The pipeline guide reviews pipeline therapeutics for Uterine Leiomyoma (Non Malignant Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Uterine Leiomyoma (Non Malignant Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Uterine Leiomyoma (Non Malignant Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Uterine Leiomyoma (Non Malignant Disorders)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Uterine Leiomyoma (Non Malignant Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Uterine Leiomyoma (Non Malignant Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

AbbVie Inc
Bayer AG
Context Therapeutics Inc
Daewoong Pharmaceutical Co Ltd
Endo International Plc
Eurofarma Laboratorios SA
Evestra Inc
GeneScience Pharmaceuticals Co Ltd
Immunitor Inc
Jiangsu Hengrui Medicine Co Ltd
Kissei Pharmaceutical Co Ltd
Livzon Pharmaceutical Group Co Ltd
Luye Pharma Group Ltd
Richter Gedeon Nyrt
TiumBio Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Uterine Leiomyoma (Uterine Fibroids) – Overview

Uterine Leiomyoma (Uterine Fibroids) – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Uterine Leiomyoma (Uterine Fibroids) – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Uterine Leiomyoma (Uterine Fibroids) – Companies Involved in Therapeutics Development

AbbVie Inc

Bayer AG

Context Therapeutics Inc

Daewoong Pharmaceutical Co Ltd

Endo International Plc

Eurofarma Laboratorios SA

Evestra Inc

GeneScience Pharmaceuticals Co Ltd

Immunitor Inc

Jiangsu Hengrui Medicine Co Ltd

Kissei Pharmaceutical Co Ltd

Livzon Pharmaceutical Group Co Ltd

Luye Pharma Group Ltd

Richter Gedeon Nyrt

TiumBio Co Ltd

Uterine Leiomyoma (Uterine Fibroids) – Drug Profiles

collagenase clostridium histolyticum – Drug Profile

Product Description

Mechanism Of Action

History of Events

CTX-30916 – Drug Profile

Product Description

Mechanism Of Action

Drug to Agonize Progesterone Receptor for Uterine Fibroids – Drug Profile

Product Description

Mechanism Of Action

DWJ-1483 – Drug Profile

Product Description

Mechanism Of Action

EC-313 – Drug Profile

Product Description

Mechanism Of Action

elagolix sodium – Drug Profile

Product Description

Mechanism Of Action

History of Events

goserelin acetate – Drug Profile

Product Description

Mechanism Of Action

leuprolide acetate – Drug Profile

Product Description

Mechanism Of Action

linzagolix choline – Drug Profile

Product Description

Mechanism Of Action

History of Events

NCE-403 – Drug Profile

Product Description

Mechanism Of Action

History of Events

SHR-7280 – Drug Profile

Product Description

Mechanism Of Action

History of Events

triptorelin acetate ER – Drug Profile

Product Description

Mechanism Of Action

triptorelin acetate SR – Drug Profile

Product Description

Mechanism Of Action

ulipristal acetate – Drug Profile

Product Description

Mechanism Of Action

History of Events

V3-Myoma – Drug Profile

Product Description

Mechanism Of Action

History of Events

vilaprisan – Drug Profile

Product Description

Mechanism Of Action

History of Events

Uterine Leiomyoma (Uterine Fibroids) – Dormant Projects

Uterine Leiomyoma (Uterine Fibroids) – Discontinued Products

Uterine Leiomyoma (Uterine Fibroids) – Product Development Milestones

Featured News & Press Releases

Feb 04, 2022: ObsEva provides update on EU marketing authorisation process for linzagolix, an oral GnRH antagonist, for the treatment of uterine fibroids

Dec 17, 2021: ObsEva Announces Positive CHMP Opinion for Linzagolix, an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids

Dec 10, 2021: ObsEva hosts symposium and presents clinical data on oral GnRH antagonist Linzagolix at SEUD Congress 2021

Dec 02, 2021: ObsEva announces symposium and presentation of clinical data on oral GnRH antagonist Linzagolix at SEUD Congress 2021

Nov 22, 2021: Obseva announces U.S. FDA acceptance of new drug application for Linzagolix

Oct 20, 2021: ObsEva presents clinical data on oral GnRH antagonist Linzagolix for the treatment of uterine fibroids at ASRM 2021 Scientific Congress & Expo

Oct 19, 2021: ObsEva announces presentation of clinical data on oral GnRH antagonist linzagolix at ASRM 2021 Scientific Congress & Expo

Sep 15, 2021: ObsEva announces submission of New Drug Application to U.S. FDA for Linzagolix for the treatment of Uterine Fibroids

Jun 30, 2021: ObsEva presents clinical data on open-label pilot study of Yselty (linzagolix) for the treatment of severe adenomyosis at ESHRE Virtual 37th Annual Meeting

Jun 24, 2021: ObsEva to present data on Yselty (linzagolix) at ESHRE Virtual 37th Annual Meeting

May 20, 2021: ObsEva announces final results from the phase 3 PRIMROSE program of Yselty (linzagolix) for the treatment of uterine fibroids

May 04, 2021: ObsEva announces enrollment completion of linzagolix phase 3 EDELWEISS 3 trial for patients with moderate to severe endometriosis-associated pain

Apr 30, 2021: ObsEva presents posters at the ACOG Annual Clinical and Scientific Virtual Meeting April 30 – May 2, 2021

Apr 27, 2021: ObsEva initiates PRIMROSE 3 bone mineral density follow-up study in PRIMROSE 1 and PRIMROSE 2 trial participants

Feb 18, 2021: Ulipristal acetate 5mg (Esmya): further restrictions due to risk of serious liver injury

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Uterine Leiomyoma (Uterine Fibroids), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Uterine Leiomyoma (Uterine Fibroids) – Pipeline by AbbVie Inc, 2022

Uterine Leiomyoma (Uterine Fibroids) – Pipeline by Bayer AG, 2022

Uterine Leiomyoma (Uterine Fibroids) – Pipeline by Context Therapeutics Inc, 2022

Uterine Leiomyoma (Uterine Fibroids) – Pipeline by Daewoong Pharmaceutical Co Ltd, 2022

Uterine Leiomyoma (Uterine Fibroids) – Pipeline by Endo International Plc, 2022

Uterine Leiomyoma (Uterine Fibroids) – Pipeline by Eurofarma Laboratorios SA, 2022

Uterine Leiomyoma (Uterine Fibroids) – Pipeline by Evestra Inc, 2022

Uterine Leiomyoma (Uterine Fibroids) – Pipeline by GeneScience Pharmaceuticals Co Ltd, 2022

Uterine Leiomyoma (Uterine Fibroids) – Pipeline by Immunitor Inc, 2022

Uterine Leiomyoma (Uterine Fibroids) – Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022

Uterine Leiomyoma (Uterine Fibroids) – Pipeline by Kissei Pharmaceutical Co Ltd, 2022

Uterine Leiomyoma (Uterine Fibroids) – Pipeline by Livzon Pharmaceutical Group Co Ltd, 2022

Uterine Leiomyoma (Uterine Fibroids) – Pipeline by Luye Pharma Group Ltd, 2022

Uterine Leiomyoma (Uterine Fibroids) – Pipeline by Richter Gedeon Nyrt, 2022

Uterine Leiomyoma (Uterine Fibroids) – Pipeline by TiumBio Co Ltd, 2022

Uterine Leiomyoma (Uterine Fibroids) – Dormant Projects, 2022

Uterine Leiomyoma (Uterine Fibroids) – Dormant Projects, 2022 (Contd..1)

Uterine Leiomyoma (Uterine Fibroids) – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Uterine Leiomyoma (Uterine Fibroids), 2022

Number of Products under Development by Companies, 2022

Number of Products by Targets, 2022

Number of Products by Stage and Targets, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently asked questions

Uterine Leiomyoma (Uterine Fibroids) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,000

Can be used by individual purchaser only

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Uterine Leiomyoma (Uterine Fibroids) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Uterine Leiomyoma (Uterine Fibroids) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.